Drug Cos. Want Blue Cross Unit Sanctioned In Aggrenox MDL

By Dani Kass · February 28, 2018, 6:04 PM EST

Boehringer Ingelheim and Teva have asked a Connecticut federal court to sanction Blue Cross and Blue Shield of Louisiana for allegedly dodging discovery in multidistrict litigation in which it's accusing the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Motion

Case Information

Case Title

In Re: Aggrenox Antitrust Litigation

Case Number

Court

Connecticut

Nature of Suit

Anti-Trust

Date Filed

April 03, 2014

Recent Articles By Dani

July 10, 2024
Drug Pricing, Overreach Dominate IP Disclaimer Feedback
May 28, 2024
Edwards Urges Full Fed. Circ. To Limit FDA Safe Harbor
April 05, 2024
Judge Lourie's Dissent Revives Debate Over FDA Safe Harbor
February 20, 2024
Fed. Circ. Backs Microsoft's PTAB Win Over 3D Patents
February 08, 2024
HHS Won't Invoke IP Rights To Lessen Xtandi Prices
January 30, 2024
CDC Patent Apps Lead Gilead To Victory In HIV Research Feud
January 11, 2024
NJ Judge Not Convinced Epidiolex Seller Lied To USPTO
December 13, 2023
The Biggest Patent Rulings Of 2023
November 17, 2023
FDA's Lack Of Power May Limit FTC's Patent Challenge
November 02, 2023
Nonprofit Calls For CMS-Amgen Price Talks To Reflect Abuse